Trials / Not Yet Recruiting
Not Yet RecruitingNCT07346690
A Study Testing the Effects of Different THC Doses on Psychological and Biological Function
Acute Dose-Dependent Effects of Oral THC on Physiological and Subjective Responses in Healthy Cannabis-Experienced Adults
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- University of Calgary · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The goal of this clinical trial is to learn how a investigational medicinal product (THC) affects psychological and physical responses in healthy adults with prior cannabis use experience. The main questions it aims to answer are: \- How do different dose levels of the investigational medicinal product (THC) influence short-term subjective and physiological responses? Researchers will compare three dose levels of the study drug to a placebo (a look-alike substance with no active ingredient) to see how responses vary across sessions. Participants will: * Attend four in-person study visits, each involving a single dose of either the study drug or placebo * Complete questionnaires about their moment-to-moment experiences * Have their heart rate, blood pressure, and other physical measures monitored * Undergo serial blood sampling to measure circulating biomarkers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AVCN319301b (6mg) | AVCN319301b is a standardized oral capsule containing a precise dose of Δ9-THC. |
| DRUG | AVCN319301b (9mg) | AVCN319301b is a standardized oral capsule containing a precise dose of Δ9-THC. |
| DRUG | AVCN319301b (15mg) | AVCN319301b is a standardized oral capsule containing a precise dose of Δ9-THC. |
| DRUG | Placebo | The matched placebo is an oral capsule identical in appearance to the active study drug and contains the same non-medicinal ingredients but no Δ9-THC. It is manufactured to match the active capsules in size, color, taste, and packaging to maintain blinding for participants and study staff. |
Timeline
- Start date
- 2026-02-01
- Primary completion
- 2028-02-01
- Completion
- 2028-02-01
- First posted
- 2026-01-16
- Last updated
- 2026-01-16
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT07346690. Inclusion in this directory is not an endorsement.